DEFR14A: BlackRock Health Sciences Term Trust Amends Proxy Statement, Announces Standstill Agreement with Karpus Management

BlackRock Health Sciences Term Trust amended its proxy statement to include a standstill agreement with Karpus Management, involving a discount management program with potential tender offers.

Summary

• BlackRock Health Sciences Term Trust (the Fund) filed an amendment to its proxy statement on May 7, 2024, related to the annual shareholder meeting on June 25, 2024.
• The amendment adds information about a standstill agreement entered into on May 3, 2024, with Karpus Management, Inc.
• The agreement includes the adoption of a discount management program where the Trust may commence tender offers to repurchase 2.5% of its outstanding Common Shares at 98% of the Trust's net asset value (NAV) per share.
• This is contingent on the Common Shares trading at an average daily discount to NAV greater than 7.50% during a three-month measurement period, starting April 1, 2024, and continuing for 12 months.
• Karpus has agreed to certain standstill covenants and to vote its Common Shares in accordance with the Board's recommendations.
• The agreement remains in effect until the earlier of May 3, 2027, 10 days before the record date for the 2027 annual meeting, or if the Trust fails to commence a required Conditional Tender Offer, or if the Trust determines not to conduct a required Conditional Tender Offer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the agreement aims to address a discount issue and align shareholder interests, but the success depends on market conditions and execution.

Positives

• The discount management program aims to reduce the discount between the share price and NAV, potentially benefiting shareholders.
• The standstill agreement with Karpus provides stability and alignment in voting decisions.
• The potential tender offers could increase demand for the shares and support the share price.

Negatives

• The tender offers are conditional and depend on the share price discount exceeding 7.50%, so there's no guarantee they will occur.
• The agreement requires Karpus to vote with the Board, which may limit their ability to advocate for changes they believe are necessary.

Risks

• The discount to NAV may not consistently exceed 7.50%, preventing the tender offers from being triggered.
• The Trust may determine not to conduct a Conditional Tender Offer even if required.
• The standstill agreement could limit Karpus's ability to act in the best interests of shareholders if their views diverge from the Board's.

Future Outlook

The Trust intends to commence tender offers if the share price discount to NAV exceeds 7.50% during measurement periods. The success of the discount management program will depend on market conditions and the Trust's ability to execute the tender offers effectively.

Industry Context

Closed-end funds often trade at discounts to their NAV. Discount management programs and standstill agreements are tools used to address these discounts and align shareholder interests. Karpus Management is known to be an activist investor in closed end funds.

Comparison to Industry Standards

• Activist investors such as Karpus Management frequently engage with closed-end funds to address discount issues, a common problem in the industry.
• Tender offers are a standard mechanism used by closed-end funds to reduce discounts to NAV, similar to strategies employed by funds like Saba Capital and Bulldog Investors.
• Standstill agreements are often part of the resolution, ensuring a period of stability and cooperation between the fund and the activist investor, as seen in other cases involving activist hedge funds and closed-end funds.

Stakeholder Impact

• Shareholders may benefit from a reduced discount to NAV and increased share price.
• The agreement provides clarity and stability for the Trust's operations.

Next Steps

• The Trust will monitor the share price discount to NAV to determine if a tender offer is required.
• The Trust will conduct the annual shareholder meeting on June 25, 2024.
• Karpus will vote its shares in accordance with the Board's recommendations.

Key Dates

Keywords

standstill agreement, tender offer, discount management program, Karpus Management, proxy statement, BlackRock Health Sciences Term Trust, NAV, shareholders